Saracatinib

Generic Name
Saracatinib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C27H32ClN5O5
CAS Number
379231-04-6
Unique Ingredient Identifier
9KD24QGH76
Background

Saracatinib has been investigated for the treatment of Cancer, Osteosarcoma, Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.

Associated Conditions
-
Associated Therapies
-

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

First Posted Date
2008-08-15
Last Posted Date
2019-04-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
19
Registration Number
NCT00735917
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇦🇺

Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

🇺🇸

University of Colorado at Denver, Aurora, Colorado, United States

and more 6 locations

Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer

First Posted Date
2008-07-21
Last Posted Date
2015-06-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
21
Registration Number
NCT00718809
Locations
🇺🇸

Indiana University Medical Center, Indianapolis, Indiana, United States

🇺🇸

Stanford University Hospitals and Clinics, Stanford, California, United States

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

First Posted Date
2008-04-29
Last Posted Date
2014-05-21
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
23
Registration Number
NCT00669019
Locations
🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma

First Posted Date
2008-04-16
Last Posted Date
2018-06-29
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
17
Registration Number
NCT00659360
Locations
🇺🇸

Fox Chase Cancer Center, Rockledge, Pennsylvania, United States

🇨🇦

Montreal General Hospital, Montreal, Quebec, Canada

🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

and more 1 locations

AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy

First Posted Date
2008-03-19
Last Posted Date
2018-08-29
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
37
Registration Number
NCT00638937
Locations
🇨🇦

McGill University Department of Oncology, Montreal, Quebec, Canada

🇨🇦

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

🇨🇦

The Ottawa Hospital Cancer Centre (Ottawa Health Research Institute) Civic Campus, Ottawa, Ontario, Canada

and more 1 locations

Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer

First Posted Date
2008-02-06
Last Posted Date
2018-08-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
21
Registration Number
NCT00607594
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

🇨🇦

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

🇨🇦

University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

and more 2 locations

AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

First Posted Date
2007-09-12
Last Posted Date
2017-12-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
23
Registration Number
NCT00528645
Locations
🇺🇸

North Central Cancer Treatment Group, Rochester, Minnesota, United States

AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

First Posted Date
2007-08-08
Last Posted Date
2018-04-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
28
Registration Number
NCT00513071
Locations
🇺🇸

City of Hope, Duarte, California, United States

© Copyright 2024. All Rights Reserved by MedPath